Indian startup Qure.AI secured USD 65 million in funding from investors led by Lightspeed Venture Partners and 360 ONE Asset Management. The funding will support expanding and enhancing its AI-based disease detection products.

The startup, founded in 2016, claims its products surpass human radiologists and physicians in identifying diseases such as tuberculosis, lung cancer, and stroke. Regulators in the US and the European Union have approved its products for use.

In a statement released Monday, the startup announced that Merck & Co.’s Merck Global Health Innovation Fund and Kae Capital joined the Series D round, along with existing investors Novo Holdings, Health Quad, and TeamFund. 

The company intends to utilize the funds to expand in the US and other markets, enhance its generative AI foundation models, and finance acquisitions.

The Mumbai-based startup’s products utilise AI to identify and manage critical diseases at more than 3,000 imaging sites across over 90 countries. 

Established in 2016, the company claims that its products outperform human radiologists and physicians in diagnosing conditions such as tuberculosis, lung cancer, and stroke. We and European Union regulators have authorized several of its products.

Prashant Warier, Qure.AI’s co-founder and chief executive officer, stated that AI is helping to address healthcare challenges. The technology is increasingly being applied in drug discovery, hospital patient management, and surgical robots.

Ready to invest like a pro? The Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists, insightful market analysis and, much more!